Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis (Q42467845)

1 November 2017

Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis (English)

1 reference

1 November 2017

D Vidal

1

1 reference

PubMed ID

15377354

1 November 2017

X Matías-Guiu

series ordinal

2

1 reference

PubMed ID

15377354

1 November 2017

A Alomar

series ordinal

3

1 reference

PubMed ID

15377354

1 November 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

British Journal of Dermatology

1 November 2017

1 reference

1 November 2017

151

1 reference

1 November 2017

3

1 reference

1 November 2017

656-662

1 reference

Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial

1 November 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06094.X

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06094.X

Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06094.X

Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06094.X

Apoptosis, cancer and cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06094.X

Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06094.X

How specific is the TUNEL reaction? An account of a histochemical study on human skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06094.X

bcl-2 protein expression in aggressive and non-aggressive basal cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06094.X

Bax expression and growth behavior of basal cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06094.X

Abnormalities of p53 protein expression in cutaneous disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06094.X

Variations of basal cell carcinomas according to gender, age, location and histopathological subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06094.X

Why classify basal cell carcinomas?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06094.X

Immunohistochemical evaluation of basal cell carcinoma and trichepithelioma using Bcl-2, Ki67, PCNA and P53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06094.X

Interferon alpha2 recombinant and epidermal growth factor modulate proliferation and hypusine synthesis in human epidermoid cancer KB cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06094.X

p53 expression related to the aggressive infiltrative histopathological feature of basal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06094.X

bcl-2 vs p53 protein expression and apoptotic rate in human nonmelanoma skin cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06094.X

Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06094.X

The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06094.X

Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06094.X

Imiquimod in basal cell carcinoma: how does it work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06094.X

Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06094.X

10.1111/J.1365-2133.2004.06094.X

21 January 2018

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wkpbfuces5dmnidqz64hfajncm

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_wkpbfuces5dmnidqz64hfajncm

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wkpbfuces5dmnidqz64hfajncm

mapped directly with Wikidata item

30 July 2022

based on heuristic

1 reference

https://api.fatcat.wiki/v0/release/wkpbfuces5dmnidqz64hfajncm